Glutamate Neurotoxicity in Glaucoma
About the Research Project
Program
Award Type
Standard
Award Amount
$50,000
Active Dates
April 01, 2000 - March 31, 2002
Grant ID
G2000010
Summary
Dr. Ayoub is exploring the role of the signaling molecule glutamate, acting through NMDA receptors, in retinal ganglion cell death. He has hypothesized that, under the high IOP conditions found in glaucoma, glutamate is released continuously. This would be an important finding if true because the prolonged presence of glutamate can be toxic to nerve cells and stimulate cell death. Dr. Ayoub is measuring glutamate and analyzing its effects on ganglion cell survival to determine the amount of glutamate that is sufficient to cause cell death. In addition, the neuroprotective action of cannabinoids is being analyzed to determine if they can suppress glutamate levels and/or suppress cell death. Dr. Ayoub has already determined the level of glutamate needed to cause neurotoxicity, and has refined his experimental approach accordingly. Clinical trials are now taking place elsewhere to determine the effects of glutamate suppressors in glaucoma, so the results of this study could prove timely.
Related Grants
National Glaucoma Research
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
National Glaucoma Research
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
National Glaucoma Research
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute